This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.
This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.
This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.
This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.
This information was originally presented at the NCCN 2017 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in San Francisco, California, on October 6, 2017.
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation.
Join Dan Douer, MD and Jae Park, MD from Memorial Sloan Kettering Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to acute lymphoblastic leukemia (ALL).
Facebook
X
LinkedIn
Forward